Towards the development of new effective antipsychotics


DOI: https://dx.doi.org/10.18565/pharmateca.2022.13.59-61

I.I. Miroshnichenko

Mental Health Research Center, Moscow, Russia
Despite the fact that antipsychotic drugs have been known for a long time, the problem of finding new effective drugs really remains relevant. This article summarizes recent advances and failures in clinical trials for new antipsychotics. The Food and Drug Administration recently approved two new antipsychotic drugs USA (FDA). The combination form of olanzapine and samidorphan is intended to miti- gate the side effects associated with the use of olanzapine. Another drug is lumateperone, which has the potential to treat patients with severe metabolic side effects. The efficacy and safety of the combined use of xanomeline and trospium in patients with schizophrenia are currently being studied. New indications of existing drugs for the treatment of schizophrenia are also considered.

About the Autors


Corresponding author: Igor I. Miroshnichenko, Dr. Sci. (Med.), Head of the Laboratory of Pharmacokinetics, Mental Health Research Center, Moscow, Russia; igormir@psychiatry.ru; ORCID: https://orcid.org/0000-0003-4950-5336; SPIN: 4117-9703


Similar Articles


Бионика Медиа